Nexus Oncology Is Acquired By Ockham, Now Expands Clinically and Geographically

Okham Development Group of Cary has acquired Nexus Oncology of Edinburgh, Scotland. These are small and powerful oncology focused CROs.

Cash-and-stock deal terms were kept undisclosed. James Baker, Nexus comes with a stable book of business and an institutional investment partner, said Ockham’s CEO. Nexus is just twelve years old and has 120 employees across Scotland, Poland, Germany, France, Sweden, Hungary, Switzerland, Belgium and Spain, in addition to Canada and the United States.

Before the acquisition took places, Ockham had 175 employees and operated primarily in the United States with satellite offices in India and the United Kingdom as well. 

Nexus initiator Clare Wareing will remain as chief scientific officer. In the meantime, Nexus Oncology will probably be known as Nexus Oncology, an Ockham Company. But Baker said by yearend Ockham is going to make a final choice on the incorporated entity’s name

 

Ockham and Nexus both compete with other small, oncology-focused CROs including Novella, Aptiv and Premier, said Baker. “The small trials we work on require a certain amount of leadership, and the large guys can’t do that as efficiently as we do,” he said.

 

Baker said, Ockham and Nexus both contend with other compact, oncology-focused CROs along with Novella, Aptiv and Premier. He also said that “The small trials we work towards need to involve a certain quantity of administration, and the substantial guys can’t do that as proficiently as we do.”